Absence of teratogenicity of indomethacin in ovarian hyperstimulation syndrome.
Eight women were treated for ovarian hyperstimulation syndrome (OHSS), grades 2-4, with indomethacin. The treatment was initiated 2-7 days after human chorionic gonadotropin administration and the period of treatment ranged between 3-8 days. The total dose was between 700-1200 mg. Nine live babies were born weighing between 2200-3950 gr. Except for a mild degree of hypospadias in one baby, there were no congenital malformations. This seems to indicate that indomethacin given under the described conditions has no apparent teratogenic effect.
D000328:Adult; D006063:Chorionic Gonadotropin / Q000009:adverse effects; D005260:Female; D005306:Fertilization; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use* / Q000633:toxicity; D007231:Infant, Newborn; D008596:Menotropins / Q000009:adverse effects; D010049:Ovarian Diseases / Q000139:chemically induced / Q000188:drug therapy*; D010062:Ovulation Induction; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*
D006063:Chorionic Gonadotropin; D008596:Menotropins; D007213:Indomethacin